Myeloma is a malignant proliferation of monoclonal plasma cells. Although morphologically
similar, several subtypes of the disease have been identified at the genetic and molecular …

Multiple myeloma is a plasma cell malignancy characterized by complex heterogeneous
cytogenetic abnormalities. The bone marrow microenvironment promotes multiple myeloma …

The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis
and chemoresistance. Several small-molecule FGF receptor (FGFR) kinase inhibitors are …

Urothelial carcinoma of the bladder is unique among epithelial carcinomas in its divergent
pathways of tumorigenesis. Low-grade papillary tumours rarely become muscle-invasive …

There appear to be 2 pathways involved in the early pathogenesis of premalignant
monoclonal gammopathy of undetermined significance (MGUS) and malignant multiple …

The fibroblast growth factor receptors (FGFR) play essential roles both during development
and in the adult. Upon ligand binding, FGFRs induce intracellular signaling networks that …

There is a strong need to better predict the survival of patients with newly diagnosed multiple
myeloma (MM). As gene expression profiles (GEPs) reflect the biology of MM in individual …

In pugilistic parlance, the one-two punch is a devastating combination of blows, with the first
punch setting the stage and the second delivering the knock-out. This analogy can be …

Fibroblast growth factors and their signaling receptors have been associated with multiple
biological activities, including proliferation, differentiation and motility. Consequently, they …

FGFR3 is frequently activated by mutation in urothelial carcinoma (UC) and represents a
potential target for therapy. In multiple myeloma, both over‐expression and mutation of …